Salesforce COO Brian Millham Trades Shares Worth $495Kby Mark Eisenberg 26.06.2024"Salesforce COO Brian Millham sold $495,621 in shares, bought $380,107 in new shares. Part of Rule 10b5-1, strong Q1, analysts ...
UnityPoint’s Neoprobe Technology Enhances Cancer Surgery Outcomesby Lilu Anderson 26.06.2024UnityPoint Health-Grinnell introduces Neoprobe Gamma Detection for precise breast cancer surgery, enhancing patient care and personalized treatment.
2 Finance Stocks Set to Beat Earnings: AGNC & Healthpeakby Mark Eisenberg 26.06.2024Discover why AGNC Investment and Healthpeak could beat earnings this quarter. Explore Zacks’ ESP tool and rankings to guide your ...
Safety Shot Expands to NY and NJ, Enlists Top Execsby Mark Eisenberg 26.06.2024"Safety Shot brings in top execs, secures $5M funding, and expands in Northeast with new wellness drinks, aiming for significant ...
US Clarifies Antitrust Enforcement in Meatpacking Industryby Mark Eisenberg 25.06.2024USDA's new rule plans to help farmers challenge unfair meatpacking practices, aiming for fairer markets and increased competition in the ...
CoinStats Breach: 1.6K Crypto Wallets Compromisedby John Darbie 25.06.2024"CoinStats breach affects nearly 1,600 crypto wallets; North Korean Lazarus Group suspected. Users urged to transfer funds and beware of ...
Smart Greenhouses Revolutionize Tomato Farming in Xinjiangby Lilu Anderson 25.06.2024Smart greenhouse in Xinjiang boosts tomato production 5-6X with advanced tech, using 1/20th the water and reducing costs by over ...
AI in Medical Diagnostics Market to Hit $30.76B by 2032, Led by Softwareby Lilu Anderson 25.06.2024"AI in Medical Diagnostics set to skyrocket to USD 30.76 billion by 2032, driven by rapid advancements and major industry ...
AI Hardware Market Poised to Surpass USD 84.9 Billion by 2031by Lilu Anderson 25.06.2024Global AI hardware market to grow from $13.3B in 2022 to $84.9B by 2031, driven by advances in tech and ...
Alnylam’s HELIOS-B Review: Conflicting Insights Analyzedby Lilu Anderson 25.06.2024Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.